Clinical trial Recruiting at 7 sites Phase 1 Interventional Ages 18 and up Women only

Alternative treatment for T4 breast cancer involving preoperative radiotherapy and immediate reconstruction

Official title: Feasibility of Preoperative Radiotherapy in T3 and T4 Breast Cancer Patients Who Are Responders to Neoadjuvant Chemotherapy to Allow for Immediate Reconstruction: a Prospective Study

Run by Memorial Sloan Kettering Cancer Center · NCT05412225 · Data updated 2026-11-12

This study is testing a new treatment for T4 breast cancer that combines radiation before surgery with immediate reconstruction to see if it can improve patient outcomes.

More Breast Cancer trials

Quick facts

PhasePhase 1
Study typeInterventional
Ages18 Years and up
SexWomen only
Enrollment60 (estimated)
SponsorMemorial Sloan Kettering Cancer Center
Academic / other
Locations7 sites (Basking Ridge, New Jersey and 6 other locations)
StatusRecruiting
StartedJune 6, 2022
Main results expectedJune 6, 2027
Study endsJune 6, 2027
Registry record updatedSeptember 24, 2026
Trial IDNCT05412225 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are females aged 18 and older with biopsy-proven invasive breast cancer and specific tumor characteristics.

Probably not a fit

Patients with prior breast cancer, stage IV disease, or those who are pregnant will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study tests a new treatment approach for T4 breast cancer that includes preoperative radiotherapy followed by mastectomy and immediate autologous reconstruction surgery. The goal is to evaluate the feasibility and safety of this alternative method compared to standard treatment practices. Participants will undergo neoadjuvant radiotherapy before their surgery, and the reconstruction will use tissue from another part of their body immediately after the mastectomy. The study aims to determine if this approach can improve outcomes for patients with invasive breast cancer.

Why it matters

Potential benefit: If successful, this treatment could provide a more effective and immediate reconstruction option for patients with T4 breast cancer.

How similar studies have gone: Other studies have explored similar approaches, but this specific combination of preoperative radiotherapy and immediate reconstruction is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Female sex, aged ≥18 years, with biopsy-proven invasive breast cancer
* cT3-4 cN0-3 tumor
* Partial or complete response to NAC on imaging and clinical examination using the Response Evaluation Criteria in Solid Tumors (RECISTv1.1) definition.
* Desire to undergo autologous reconstruction and assessed to be an appropriate candidate by a plastic and reconstructive surgeon
* Able to read and understand English

Exclusion Criteria:

* Prior ipsilateral breast cancer
* Bilateral breast cancer
* Pregnant
* Stage IV disease at presentation
* Stable disease or progressive disease after NAC
* Surgically unresectable breast disease
* BMI \>40
* Prior history of thoracic radiotherapy

Where it's running

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
    Basking Ridge, New Jersey, United States
    Recruiting
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
    Middletown, New Jersey, United States
    Recruiting
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
    Montvale, New Jersey, United States
    Recruiting
  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activity)
    Commack, New York, United States
    Recruiting
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)
    Harrison, New York, United States
    Recruiting
  • Memorial Sloan Kettering Cancer Center
    New York, New York, United States
    Recruiting
Show 1 more location
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)
    Uniondale, New York, United States
    Recruiting

Study contacts

  • Principal investigator: Minna Lee, MD — Memorial Sloan Kettering Cancer Center
  • Study coordinator: Minna Lee, MD
  • Email: leem15@mskcc.org
  • Phone: 646-888-6898

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.